

**IN THE UNITED STATES PATENT & TRADEMARK OFFICE**

Applicant:	Walzer, Peter D.	: Examiner:	Unknown
Serial No.	10/595,999	: Group Art Unit:	Unknown
Filed:	05/24/2006	: Atty. Ref.:	0091830.0542088
For:	<b>BISBENZAMIDINES FOR THE TREATMENT OF PNEUMONIA</b>		

---

**AMENDMENT AND RESPONSE**

MS RCE  
COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action, dated September 17, 2007, please consider the following remarks.

**Remarks** begin on page 2 of this paper.

**Remarks**

The Notification to comply with requirements for patent applications containing nucleotide and/or amino acid sequence disclosures sent on September 17, 2007 indicates that the application clearly fails to comply with the requirements of 37 CFR 1.821-1.825, and that a copy of the "Sequence Listing" in computer readable form must be submitted as required by 37 CFR 1.821(e).

The application does not contain any sequence that falls under 37 CFR 1.821-1.825, and consequently there is no requirement to submit a copy of the "Sequence Listing" in computer readable form. If this assertion is incorrect, please specifically point out the location of the sequence in the application so that the application may be amended to comply with 37 CFR 1.821-1.825.

Respectfully Submitted,

/Scott R. Conley, Ph.D./  
Scott R. Conley, Ph.D. (Reg. No. 57,289)  
Frost Brown Todd LLC  
2200 PNC Center  
201 E. Fifth Street  
Cincinnati, Ohio 45202-4182  
513-651-6818 (direct)  
513-651-6981 (fax)